

CITATION REPORT

List of articles citing

Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart

DOI: 10.1161/01.CIR.93.4.704
Circulation, 1996, 93, 704-11.

Source: <https://exaly.com/paper-pdf/86224855/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
722	Regulation of nitric oxide synthase gene expression by cytokines. 1996 , 2, S179-85		13
721	Basic mechanisms in heart failure: the cytokine hypothesis. 1996 , 2, 243-9		338
720	Stress activated cytokines and the heart. 1996 , 7, 341-54		78
719	Molecular pharmacology and pathophysiological significance of endothelin. 1996 , 72, 261-90		134
718	Role of cytokines in myocardial ischemia and reperfusion. 1997 , 6, 175-83		43
717	Cytokines and cardiomyocyte death. 1997 , 29, 339-43		90
716	Soluble tumor necrosis factor receptors are elevated in relation to severity of congestive heart failure. 1997 , 61, 657-64		44
715	Cardiac-specific overexpression of tumor necrosis factor-alpha causes lethal myocarditis in transgenic mice. 1997 , 3, 117-24		130
714	Effect of tumour necrosis factor-alpha on proliferation, activation and protein synthesis of rat hepatic stellate cells. 1997 , 27, 1067-80		68
713	Inducible nitric oxide synthase and tumor necrosis factor-alpha in myocardium in human dilated cardiomyopathy. 1997 , 29, 716-24		116
712	Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation. 1997 , 30, 35-41		103
711	Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. 1997 , 30, 997-1001		159
710	Anti-tumor necrosis factor-alpha improves myocardial recovery after ischemia and reperfusion. 1997 , 30, 1554-61		131
709	Adrenomedullin in experimental congestive heart failure: cardiorenal activation. 1997 , 273, R1392-9		16
708	Transient, isopeptide-specific induction of myocardial endothelin-1 mRNA in congestive heart failure in rats. 1997 , 273, H1727-36		23
707	Apoptosis and congestive heart failure. 1997 , 7, 249-55		28
706	Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. 1997 , 79, 1426-30		311

705	Serum levels of soluble form of Fas molecule in patients with congestive heart failure. 1997 , 79, 1698-701	55
704	Molecular and cellular mechanisms of myocardial failure. 1997 , 80, 15L-25L	242
703	Circulating interleukin-6 in severe heart failure. 1997 , 79, 1128-31	181
702	Distribution of myocardial macrophages in the normal human heart. 1997 , 191 (Pt 3), 417-23	22
701	Nasal nitric oxide concentration is decreased in heart failure patients receiving nitrates. 1998 , 12, 95-100	1
700	Serum interleukin-6 in congestive heart failure secondary to idiopathic dilated cardiomyopathy. 1998 , 82, 688-90, A8	77
699	Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol. 1998 , 41, 17-24	129
698	Tumor necrosis factor in congestive heart failure: a mechanism of disease for the new millennium?. 1998 , 41, 25-30	43
697	New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress. 1998 , 352 Suppl 1, S134-8	96
696	Amelioration of liver damage induced by ischemia and reperfusion with FR167653; a newly synthesized cytokine suppressive antiinflammatory drug. 1998 , 30, 49-52	6
695	Tumor necrosis factor-alpha is persistently expressed in cardiac allografts in the absence of histological or clinical evidence of rejection. 1998 , 30, 875-7	25
694	Increased myocardial tumor necrosis factor-alpha in a crystalloid-perfused model of cardiac ischemia-reperfusion injury. 1998 , 65, 439-43	103
693	Denopamine, a beta1-adrenergic agonist, prolongs survival in a murine model of congestive heart failure induced by viral myocarditis: suppression of tumor necrosis factor-alpha production in the heart. 1998 , 32, 808-15	19
692	Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. 1998 , 32, 955-63	146
691	The role of cytokines in the failing human heart. 1998 , 16, 645-56, viii	92
690	Nitric oxide in the failing myocardium. 1998 , 16, 657-64, viii	19
689	Evidence of phenotypic alteration as a cause of systolic dysfunction in the failing heart. 1998 , 16, 677-89, ix	
688	The pathophysiology of advanced heart failure. 1998 , 135, S216-30	63

687	Predicting short-term outcome in severely ill heart failure patients: implications regarding listing for urgent cardiac transplantation and patient selection for temporary ventricular assist device support. 1998 , 4, 169-75	7
686	Role of nitric oxide in ventricular dysfunction. 1998 , 4, 249-60	2
685	Medical therapy of chronic heart failure. Role of ACE inhibitors and beta-blockers. 1998 , 16, 711-25, ix	8
684	Ketamine inhibits the proinflammatory cytokine-induced reduction of cardiac intracellular cAMP accumulation. 1998 , 87, 1015-9	10
683	Ketamine Inhibits the Proinflammatory Cytokine-Induced Reduction of Cardiac Intracellular cAMP Accumulation. 1998 , 87, 1015-1019	22
682	IL-1 beta alters the expression of the receptor tyrosine kinase gene r-EphA3 in neonatal rat cardiomyocytes. 1998 , 274, H331-41	5
681	Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure. 1998 , 275, H250-8	44
680	Regulation of intrarenal blood flow in experimental heart failure: role of endothelin and nitric oxide. 1998 , 274, F766-74	21
679	Tumor necrosis factor in the heart. 1998 , 274, R577-95	276
678	Angiotensin II and mechanical stretch induce production of tumor necrosis factor in cardiac fibroblasts. 1999 , 276, H1968-76	40
677	Differential regulation of cardiac expression of IL-6 and TNF-alpha by A2- and A3-adenosine receptors. 1999 , 276, H2141-7	17
676	Myocardial tumor necrosis factor-alpha secretion in hypertensive and heart failure-prone rats. 1999 , 277, H543-50	21
675	Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. 1999 , 277, H777-87	50
674	Molecular mechanisms of myocardial remodeling. 1999 , 79, 215-62	1299
673	Clinical implications of tumour necrosis factor alpha antagonism in patients with congestive heart failure. 1999 , 58 Suppl 1, I103-6	8
672	Cytokines increase neonatal cardiac myocyte calcium concentrations: the involvement of nitric oxide and cyclic nucleotides. 1999 , 19, 645-53	17
671	Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. 1999 , 83, 376-82	390
670	Effects of amiodarone on tumor necrosis factor-alpha levels in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. 1999 , 83, 388-91	22

669	Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failure. 1999 , 83, 1500-3, A8	67
668	Circulating leptin in patients with chronic obstructive pulmonary disease. 1999 , 159, 1215-9	140
667	The pathophysiology of advanced heart failure. 1999 , 28, 87-101	43
666	The changes of circulating tumor necrosis factor levels in patients with congestive heart failure influenced by therapy. 1999 , 69, 77-82	34
665	Elevated tumor necrosis factor alpha of blood mononuclear cells in patients with congestive heart failure. 1999 , 71, 257-61	25
664	Endotoxin and immune activation in chronic heart failure: a prospective cohort study. 1999 , 353, 1838-42	644
663	The role of TNF in cardiovascular disease. 1999 , 40, 97-105	131
662	Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. 1999 , 33, 1935-42	108
661	Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. 1999 , 34, 2061-7	193
660	Inducible nitric oxide synthase and tumor necrosis factor in animal models of myocardial necrosis induced by coronary artery ligation or isoproterenol injection. 1999 , 5, 236-45	18
659	Kinetics of tumor necrosis factor alpha in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor alpha in acute myocardial infarction. 1999 , 137, 1145-52	82
658	Role of TNF in mediating renal insufficiency following cardiac surgery: evidence of a postbypass cardiorenal syndrome. 1999 , 85, 185-99	81
657	High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: a possible mechanism of digitalis toxicity. 1999 , 63, 934-40	51
656	Anti-inflammatory cytokine profile in human heart failure: behavior of interleukin-10 in association with tumor necrosis factor-alpha. 1999 , 63, 951-6	46
655	Cytokines in heart failure: pathogenetic mechanisms and potential treatment. 1999 , 111, 423-8	47
654	Tumor necrosis factor-alpha: a mediator of disease progression in the failing human heart. 1999 , 115, 1170-4	52
653	Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. 1999 , 115, 836-47	299
652	How are cytokines activated in heart failure?. 1999 , 1, 309-12	44

651	Preoperative and postoperative endotoxemia in children with congenital heart disease. 2000 , 117, 1706-12	91
650	Mitral valve repair in heart failure. 2000 , 2, 365-71	35
649	Transient rise in serum soluble Fas (APO-1/CD95) in patients undergoing cardiac surgery. 2000 , 24, 628-31	9
648	Expression of tumor necrosis factor-alpha protein in the myocardium in fatal myocarditis. 2000 , 42, 43-7	6
647	Defects in insulin action in chronic heart failure. 2000 , 2, 203-12	9
646	Aldosterone, a new appreciation of its role in heart failure. 2000 , 20, 1107-15	7
645	Clinical and neurohormonal correlates of circulating granulocyte-macrophage colony-stimulating factor in severe heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. 2000 , 86, 707-10, A9-10	21
644	Beneficial effects of nitric oxide on cardiac diastolic function: 'the flip side of the coin'. 2000 , 5, 337-44	24
643	Insights into pathogenesis and treatment of cytokines in cardiomyopathy. 2000 , 2, 120-8	10
642	Ventricular unloading and myocyte recovery: insight gained into the pathophysiology of congestive heart failure. 2000 , 2, 181-8	5
641	The role of tumor necrosis factor alpha in the pathophysiology of congestive heart failure. 2000 , 2, 189-97	26
640	Role of TNF-alpha in myocardial dysfunction after hemorrhagic shock and lower-torso ischemia. 2000 , 278, H942-50	20
639	Role of NO and PAF in the impairment of skeletal muscle contractility induced by TNF-alpha. 2000 , 279, R2156-63	33
638	A direct requirement of nuclear factor-kappa B for suppression of apoptosis in ventricular myocytes. 2000 , 279, H939-45	78
637	Effects of cardiotrophin-1 on hemodynamics and endocrine function of the heart. 2000 , 279, H388-96	24
636	New therapies for heart failure: is thalidomide the answer?. 2000 , 93, 305-11	24
635	Acute Congestive Heart Failure and Tumor Necrosis Factor Alpha. 2000 , 9, 76-80	5
634	The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. 2000 , 161, 1179-84	258

633	Activation of cytokines as a mechanism of disease progression in heart failure. 2000 , 59 Suppl 1, i90-3	17
632	Tumour necrosis factor-alpha expression in idiopathic dilated cardiomyopathy: correlation to myocardial inflammatory activity. 2000 , 12, 1261-6	18
631	Inflammation, hormones, the blood and the heart; are cardiologists learning to be internists again?. 2000 , 72, 203-5	3
630	Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. 2000 , 76, 125-33	112
629	The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1. 2000 , 72, 175-86	140
628	Inflammatory mediators in heart failure. 2000 , 72, 209-13	31
627	The changes of circulating tumor necrosis factor levels in congestive heart failure influenced by varied classes of therapy. 2000 , 72, 297-298	
626	Circulating levels of cytokines and their site of production in patients with mild to severe chronic heart failure. 2000 , 140, E28	47
625	Prognostic value of serum cytokines in patients with congestive heart failure. 2000 , 19, 419-25	102
624	Expression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage congestive heart failure. 2000 , 19, 819-24	111
623	Circulating interleukin-6 significantly correlates to thyroid hormone in acute myocardial infarction but not in chronic heart failure. 2000 , 23, 509-14	6
622	From the sarcomere to the nucleus: role of genetics and signaling in structural heart disease. 2000 , 1, 179-223	56
621	Role of tumour necrosis factor-alpha in the progression of heart failure: therapeutic implications. 2000 , 59, 745-51	28
620	Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications. 2000 , 60, 1245-57	58
619	Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. 2000 , 35, 1590-8	224
618	Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. 2000 , 36, 208-12	88
617	Expression of tumor necrosis factor-alpha--converting enzyme and tumor necrosis factor-alpha in human myocarditis. 2000 , 36, 1288-94	49
616	Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy: the CARDIGENE study. 2000 , 35, 29-35	56

615	The role of tumor necrosis factor in the pathophysiology of heart failure. 2000 , 35, 537-44	377
614	UV light synergistically enhances the cardiotoxic effects of interleukin 1beta through peroxynitrite formation. 2001 , 7, 165-75	3
613	Relationship between plasma levels of cardiac natriuretic peptides and soluble Fas: plasma soluble Fas as a prognostic predictor in patients with congestive heart failure. 2001 , 7, 322-8	21
612	Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. 2001 , 37, 412-7	190
611	Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. 2001 , 37, 2086-92	76
610	Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure--modulatory effect of intravenous immunoglobulin. 2001 , 38, 187-93	82
609	Leukocyte mitochondria depolarization and apoptosis in advanced heart failure: clinical correlations and effect of therapy. 2001 , 38, 1693-700	14
608	Decreased plasma concentration of brain natriuretic peptide as a potential indicator of cardiac recovery in patients supported by mechanical circulatory assist systems. 2001 , 38, 1942-9	73
607	Ethanol infusion increases ANP and p21 gene expression in isolated perfused rat heart. 2001 , 281, 328-33	21
606	Chronic Chagas' disease cardiomyopathy patients display an increased IFN-gamma response to Trypanosoma cruzi infection. 2001 , 17, 99-107	142
605	Overexpression of tumor necrosis factor- alpha activates both anti- and pro-apoptotic pathways in the myocardium. 2001 , 33, 1331-44	104
604	Pathophysiology of chronic heart failure. 2001 , 110 Suppl 7A, 37S-46S	177
603	Effect of metoprolol on cytokine levels in chronic heart failure--a substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF). 2001 , 141, 418-21	51
602	TGF-beta1 gene polymorphisms in patients with end-stage heart failure. 2001 , 20, 979-84	45
601	The isoprostane 8-epi-PGF(2alpha) is a valuable indicator of oxidative injury in human heart valves. 2001 , 10, 241-5	17
600	Myocardial tumor necrosis factor-alpha expression does not correlate with clinical indices of heart failure in patients on left ventricular assist device support. 2001 , 72, 2044-50	23
599	Managing heart failure with immunomodulatory agents. 2001 , 19, 617-25	7
598	Nutritional strategy in the management of heart failure in adults. 2001 , 1, 363-73	25

597	C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. 2001 , 33, 37-47	152
596	Elevated serum levels of soluble interleukin-2 receptor, neopterin and beta-2-microglobulin in idiopathic dilated cardiomyopathy: relation to disease severity and autoimmune pathogenesis. 2001 , 3, 155-63	23
595	DNA enzyme targeting TNF-alpha mRNA improves hemodynamic performance in rats with postinfarction heart failure. 2001 , 281, H2211-7	34
594	Molecular and cellular mechanisms of cardiotoxicity. 2001 , 109 Suppl 1, 27-34	60
593	Early activation of IKKbeta during in vivo myocardial ischemia. 2001 , 280, H1264-71	58
592	Effects of soluble TNF receptor treatment on lipopolysaccharide-induced myocardial cytokine expression. 2001 , 280, H2281-91	33
591	The role of tumor necrosis factor in cardiac disease. 2001 , 3, 319-25	5
590	Pretransplant cachexia and morbid obesity are predictors of increased mortality after heart transplantation. 2001 , 72, 277-83	80
589	A glossary of circulating cytokines in chronic heart failure. 2001 , 3, 517-26	94
588	Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: a report from the Vesnarinone Trial. 2001 , 120, 453-9	16
587	Elevated interleukin-1beta in pericardial fluid of patients with ischemic heart disease. 2001 , 12, 567-71	17
586	The role of apoptotic cell death in cardiovascular disease. 2001 , 170, 132-40	8
585	Cytokines as new treatment targets in chronic heart failure. 2001 , 2, 271-277	34
584	The role of interleukin-6 in the failing heart. 2001 , 6, 95-103	138
583	The effect of cytokines on cardiac allograft function: tumor necrosis factor alpha a mediator of chronic injury. 2001 , 6, 137-41	1
582	Mitral valve reconstruction in the patient with heart failure. 2001 , 6, 177-85	27
581	Recent insights into the role of tumor necrosis factor in the failing heart. 2001 , 6, 71-80	65
580	The role of anti-cytokine therapy in the failing heart. 2001 , 6, 143-51	17

579	Nitric oxide synthase activity in peripheral polymorphonuclear leukocytes in patients with chronic congestive heart failure. 2001 , 87, 183-7	13
578	Evidence for increased peripheral production of tumor necrosis factor-alpha in advanced congestive heart failure. 2001 , 88, 578-81	12
577	When cancer and heart failure cross paths: a case report of severe cardiorenal compromise associated with the anti-CD20 monoclonal antibody rituximab in a patient with dilated cardiomyopathy. 2001 , 7, 223-227	4
576	The Inflammatory Response to Cardiopulmonary Bypass Should It Be Treated?. 2001 , 5, 229-235	2
575	The Syndrome of Cardiac Cachexia. 2001 , 93-103	
574	Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. 2001 , 276, 3361-70	175
573	Uncoupling protein 3 transcription is regulated by peroxisome proliferator-activated receptor (alpha) in the adult rodent heart. 2001 , 15, 833-45	205
572	Subacute and chronic effects of quinapril on cardiac cytokine expression, remodeling, and function after myocardial infarction in the rat. 2002 , 39, 842-50	32
571	Differential expression of TNF-alpha, IL-6, and IGF-1 by graded mechanical stress in normal rat myocardium. 2002 , 282, H926-34	45
570	Chromogranin A and tumor necrosis factor-alpha (TNF) in chronic heart failure. 2000 , 482, 351-9	47
569	Effect of thalidomide in patients with chronic heart failure. 2002 , 144, 847-50	42
568	Plasma concentrations of tumor necrosis factor-alpha in cats with congestive heart failure. 2002 , 63, 640-2	16
567	Current limitations in treatment of heart failure: new avenues and treatment options. 2002 , 13, S53-6	5
566	Ischemia alone is sufficient to induce TNF-alpha mRNA and peptide in the myocardium. 2002 , 17, 114-9	72
565	Myocardial inflammatory activation in children with congenital heart disease. 2002 , 30, 827-32	39
564	Involvement of inducible nitric oxide synthase in cardiac dysfunction with tumor necrosis factor-alpha. 2002 , 282, H2159-66	35
563	Alterations in immunocyte tumor necrosis factor receptor and apoptosis in patients with congestive heart failure. 2002 , 236, 254-60	4
562	TNFalpha transport across the blood-brain barrier is abolished in receptor knockout mice. 2002 , 174, 193-200	154

561	Reactive oxygen species induce cardiomyocyte apoptosis partly through TNF-alpha. 2002 , 18, 179-83	43
560	Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure. 2002 , 39, 653-63	199
559	The interleukin-6/interleukin-6-receptor system is activated in donor hearts. 2002 , 39, 1508-12	70
558	Dysfunction of mitochondrial respiratory chain complex I in human failing myocardium is not due to disturbed mitochondrial gene expression. 2002 , 40, 2174-81	106
557	Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure. 2002 , 8, 306-14	26
556	Tumor necrosis factor-alpha blockade as a therapeutic strategy in heart failure (RENEWAL and ATTACH): unsuccessful, to be specific. 2002 , 8, 365-8	19
555	Circulating levels of interleukin 18 reflect etiologies of heart failure: Th1/Th2 cytokine imbalance exaggerates the pathophysiology of advanced heart failure. 2002 , 8, 21-7	52
554	Treatment of heart failure in patients with diabetes mellitus. 2002 , 62, 285-307	5
553	Losing heart: the role of apoptosis in heart disease--a novel therapeutic target?. 2002 , 16, 135-46	250
552	Soluble tumor necrosis factor receptor levels identify a subgroup of heart failure patients with increased cardiomyocyte apoptosis. 2002 , 320, 65-7	10
551	Early and persistent activation of myocardial apoptosis, bax and caspases: insights into mechanisms of progression of heart failure. 2002 , 8, 183-192	26
550	Cytokines and anti-cytokine therapeutic approaches to chronic heart failure. 2002 , 13, 356	5
549	Chronic heart failure: an example of a systemic chronic inflammatory disease resulting in cachexia. 2002 , 85, 33-49	68
548	The syndrome of cardiac cachexia. 2002 , 85, 51-66	219
547	Chronic heart failure and skeletal muscle catabolism: effects of exercise training. 2002 , 85, 141-9	65
546	Cytokines, apoptosis and cachexia: the potential for TNF antagonism. 2002 , 85, 161-71	121
545	Importancia del factor de necrosis tumoral alfa en la patogenia de la insuficiencia cardíaca. 2002 , 55, 61-66	11
544	Decreased hematopoiesis in bone marrow of mice with congestive heart failure. 2002 , 282, R166-72	94

543	Inhibition of NOS II prevents cardiac dysfunction in myocardial infarction and congestive heart failure. 2002 , 283, H339-45	36
542	Structural, functional, and molecular characterization of the SHHF model of heart failure. 2002 , 283, H1775-84	76
541	Immune and neurohormonal pathways in chronic heart failure. 2002 , 8, 23-8, 48	23
540	The role of tumor necrosis factor alpha blockade in the treatment of congestive heart failure. 2002 , 8, 275-9	22
539	Lipopolysaccharide administration increases acid and alkaline phosphatase reactivity in the cardiac muscle. 2002 , 58, 421-6	9
538	The role of inflammation in the pathogenesis of heart failure. 2002 , 4, 200-5	13
537	Sequential monitoring of intragraft cytokine mRNA expression in relation to diastolic left ventricular wall thickness and function early after heart transplantation. 2002 , 16, 433-41	6
536	Molecular and cellular mechanisms of myocardial remodeling. 2002 , 9, 319-27	21
535	Chronic heart failure and the immune system. 2002 , 23, 325-40	16
534	Mechanisms of apoptosis in the heart. 2003 , 23, 447-59	104
533	Cellular remodeling in heart failure disrupts K(ATP) channel-dependent stress tolerance. 2003 , 22, 1732-42	73
532	Role of nitric oxide in the pathophysiology of heart failure. 2003 , 8, 35-46	32
531	Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. 2003 , 91, 18F-40F	85
530	Percutaneous transvenous mitral valvulotomy normalizes elevated circulating levels of tumor necrosis factor-alpha and interleukin-6 in mitral stenosis with heart failure. 2003 , 91, 1018-20, A8	9
529	Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. 2003 , 33, 648-56	72
528	[Prognostic value of serum levels of tumor necrosis factor-alpha in patients with heart failure]. 2003 , 56, 160-7	3
527	The role of anticytokine therapy in heart failure: recent lessons from preclinical and clinical trials?. 2003 , 87, 419-40	9
526	Oxidative stress-induced signal transduction pathways in cardiac myocytes: involvement of ROS in heart diseases. 2003 , 5, 789-94	167

525	Stress-activated cytokines and the heart: from adaptation to maladaptation. 2003 , 65, 81-101	223
524	The emerging role of pharmacogenomics in the treatment of patients with heart failure. 2003 , 76, S2246-53	4
523	NCAM(CD56) and RUNX1(AML1) are up-regulated in human ischemic cardiomyopathy and a rat model of chronic cardiac ischemia. 2003 , 163, 1081-90	42
522	Serum nitrate and nitrite in dogs with spontaneous cardiac disease. 2003 , 17, 315-8	24
521	Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. 2003 , 83, 59-115	523
520	On-pump coronary artery bypass surgery activates human myocardial NF-kappaB and increases TNF-alpha in the heart. 2003 , 112, 175-9	25
519	Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. 2003 , 308, 480-5	204
518	Delayed dilated cardiomyopathy for major burn injuries. 2003 , 29, 343-8	9
517	Cardiomyocyte death in patients with end-stage heart failure before and after support with a left ventricular assist device: low incidence of apoptosis despite ubiquitous mediators. 2003 , 22, 1028-36	31
516	Cytokines and immune activation in systolic heart failure: the role of Type D personality. 2003 , 17, 304-9	108
515	Elevated plasma amylase levels in advanced chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy: correlation with circulating interleukin-6 activity. 2003 , 23, 329-33	9
514	Changes of peripheral A2A adenosine receptors in chronic heart failure and cardiac transplantation. 2003 , 17, 280-2	76
513	Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. 2003 , 5, 609-14	126
512	Tumor necrosis factor gene polymorphism is associated with enhanced systemic inflammatory response and increased cardiopulmonary morbidity after cardiac surgery. 2003 , 97, 944-949	65
511	Cellular FLICE-inhibitory protein: an attractive therapeutic target?. 2003 , 7, 559-73	78
510	Mediators in HIV-associated cardiovascular disease: a focus on cytokines and genes. 2003 , 17 Suppl 1, S29-35	13
509	Serum tumour necrosis factor-alpha, interleukin-2 and interleukin-10 activation in stable angina and acute coronary syndromes. 2003 , 14, 431-8	76
508	Viral causes of cardiac inflammation. 2003 , 18, 182-8	31

507	Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. 2003 , 5, 33-40	126
506	Alterations in apoptotic signaling in human idiopathic cardiomyopathic hearts in failure. 2003 , 284, H268-76	47
505	Calcium-dependent arrhythmias in transgenic mice with heart failure. 2003 , 284, H431-41	92
504	Increased plasma levels of tumor necrosis factor-alpha in asymptomatic/"indeterminate" and Chagas disease cardiomyopathy patients. 2003 , 98, 407-11	88
503	Overexpression of tumor necrosis factor-alpha increases production of hydroxyl radical in murine myocardium. 2003 , 284, H449-55	33
502	Serum but not myocardial TNF-alpha concentration is increased in pacing-induced heart failure in rabbits. 2003 , 285, R463-9	31
501	Differing phagocytic function of monocytes and neutrophils in Chagas' cardiopathy according to the presence or absence of congestive heart failure. 2004 , 37, 447-53	5
500	Etanercept: Questions and Answers. 2004 , 10a, 4-6	
499	Expression of inducible nitric oxide synthase is increased in patients with heart failure due to ischemic disease. 2004 , 37, 1313-20	29
498	Functional and morphological skeletal muscle abnormalities correlate with reduced electromyographic activity in chronic heart failure. 2004 , 11, 155-61	27
497	Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. 2004 , 63, 1538-43	111
496	Pentoxifylline in ischemic, hypertensive and idiopathic-dilated cardiomyopathy: effects on left-ventricular function, inflammatory cytokines and symptoms. 2004 , 6, 195-201	29
495	Transcardiac increase in tumor necrosis factor-alpha and left ventricular end-diastolic volume in patients with dilated cardiomyopathy. 2004 , 6, 173-80	17
494	Soluble TNF-alpha and interleukin-6 receptors in the urine of heart failure patients. Their clinical value and relationship with plasma levels. 2004 , 6, 877-82	11
493	Restrictive filling pattern is associated with increased humoral activation and impaired exercise capacity in dilated cardiomyopathy. 2004 , 6, 735-43	12
492	Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation. 2004 , 126, 85-92	46
491	Molecular genetics and genomics of heart failure. 2004 , 5, 811-25	129
490	Overexpression of tumor necrosis factor (TNF)alpha and TNFalpha receptor I in human viral myocarditis: clinicopathologic correlations. 2004 , 17, 1108-18	60

489	Inflammation and chronic heart failure-potential therapeutic role of intravenous immunoglobulin. 2004 , 3, 221-7	34
488	Role of adenosine monophosphate deaminase-1 gene polymorphism in patients with congestive heart failure (influence on tumor necrosis factor-alpha level and outcome). 2004 , 93, 1260-4	20
487	Comparison of circulating levels of interleukin-6 and tumor necrosis factor-alpha in hypertrophic cardiomyopathy and in idiopathic dilated cardiomyopathy. 2004 , 94, 249-51	50
486	Nitric oxide and promotion of cardiac myocyte apoptosis. 2004 , 263, 35-53	19
485	New pharmacological strategies in chronic heart failure. 2004 , 18, 491-501	4
484	Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. 2004 , 370, 238-50	89
483	Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?. 2004 , 50, 1040-50	81
482	Therapeutic potential of anticytokine therapy in congestive heart failure. 2004 , 4, 169-77	9
481	Selective intestinal decontamination in advanced chronic heart failure: a pilot trial. 2004 , 6, 483-91	65
480	Interleukin-1 beta inhibits Na ⁺ -K ⁺ ATPase activity and protein expression in cardiac myocytes. 2004 , 26, 1-8	12
479	Wasting of the left ventricle in patients with cardiac cachexia: a cardiovascular magnetic resonance study. 2004 , 97, 15-20	25
478	Leptin deficiency enhances myocardial necrosis and lethality in a murine model of viral myocarditis. 2004 , 75, 1435-47	28
477	Change in circulating cytokines after 2 forms of exercise training in chronic stable heart failure. 2004 , 147, 100-5	68
476	Cigarette smoking and inflammatory indices in coronary artery disease. 2004 , 93, 169-74	21
475	The impact of heparin-coated cardiopulmonary bypass circuits on pulmonary function and the release of inflammatory mediators. 2004 , 98, 1586-1594	34
474	Muscle wastage in chronic heart failure, between apoptosis, catabolism and altered anabolism: a chimaeric view of inflammation?. 2004 , 7, 435-41	40
473	Cytokine response to pulmonary thromboendarterectomy. 2004 , 126, 135-41	56
472	The response of the failing heart to chronic mechanical unloading. 2004 , 19, 270-7	1

471	Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattractant protein-1 and inflammation in hypertensive heart disease. 2004 , 22, 583-92	23
470	Ongoing myocardial damage in chronic heart failure is related to activated tumor necrosis factor and Fas/Fas ligand system. 2004 , 68, 747-50	54
469	Adiponectin, T-cadherin and tumour necrosis factor-alpha in damaged cardiomyocytes from autopsy specimens. 2005 , 33, 236-44	34
468	Inflammation, cardiovascular disease and nocturnal hemodialysis. 2005 , 14, 538-42	9
467	The neurohormonal axis and biochemical markers of heart failure. 2005 , 15, 333-44	8
466	SOCS1/JAB likely mediates the protective effect of cardiotrophin-1 against lipopolysaccharide-induced left ventricular dysfunction in vivo. 2005 , 69, 1412-7	15
465	The dilemma of the strive for apoptosis in oncology: mind the heart. 2005 , 53, 101-13	9
464	The distribution of cardiac macrophages in myocardial ischaemia and cardiomyopathy. 2005 , 46, 314-9	29
463	Targeted anticytokine therapy and the failing heart. 2005 , 95, 9C-16C; discussion 38C-40C	76
462	Reduced immune responses to an aseptic inflammation in mice with congestive heart failure. 2005 , 75, 156-63	9
461	TNFalpha mediates sepsis-induced impairment of basal and leucine-stimulated signaling via S6K1 and eIF4E in cardiac muscle. 2005 , 94, 419-31	22
460	Disruptions and detours in the myocardial matrix highway and heart failure. 2005 , 2, 10-7	15
459	Update of TNF-alpha antagonists and cardiovascular disease in rheumatoid arthritis. 2005 , 7, 395-9	3
458	Reversal of maladaptive gene program in left ventricular myocardium of dogs with heart failure following long-term therapy with the Acorn Cardiac Support Device. 2005 , 10, 157-63	7
457	Halothane potentiates the alcohol-adduct induced TNF-alpha release in heart endothelial cells. 2005 , 5, 3	1
456	Skeletal muscle myofibrillar protein metabolism in heart failure: relationship to immune activation and functional capacity. 2005 , 288, E685-92	39
455	Enhanced matrix metalloproteinase activity in skeletal muscles of rats with congestive heart failure. 2005 , 289, R389-R394	13
454	Serum markers of angiogenesis and myocardial ultrasonic tissue characterization in patients with dilated cardiomyopathy. 2005 , 7, 689-95	11

453	Balance between plasma levels of tumor necrosis factor-alpha and interleukin-10 in rheumatic mitral stenosis. 2005 , 104, 171-5	10
452	Myocardial cytokine gene expression is higher in aortic stenosis than in idiopathic dilated cardiomyopathy. 2005 , 91, 926-31	37
451	Fas-associated death-domain protein inhibits TNF-alpha mediated NF-kappaB activation in cardiomyocytes. 2005 , 289, H2073-80	9
450	Peroxynitrite is a potent inhibitor of NF-{kappa}B activation triggered by inflammatory stimuli in cardiac and endothelial cell lines. 2005 , 280, 34878-87	62
449	Tumor necrosis factor alpha, rapid ventricular tachyarrhythmias, and infarct size in canine models of myocardial infarction. 2005 , 45, 153-9	32
448	Effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on cardiovascular alterations in endotoxemia. 2005 , 103, 92-100	8
447	Novel neurohormonal antagonist strategies: vasopressin antagonism, anticytokine therapy, and endothelin antagonism in patients who have heart failure. 2005 , 1, 103-27	1
446	Novel pathogenetic mechanisms in myocarditis: nitric oxide signaling. 2005 , 1, 345-61	
445	Immunomodulatory and immunoadsorptive treatments. 2005 , 1, 457-65	2
444	Antiviral treatment of myocarditis and acute dilated cardiomyopathy. 2005 , 1, 467-74	8
443	Inhibitor-kappaB kinase-beta regulates LPS-induced TNF-alpha production in cardiac myocytes through modulation of NF-kappaB p65 subunit phosphorylation. 2005 , 289, H2103-11	43
442	Inhibition of cyclooxygenase-2 enhances myocardial damage in a mouse model of viral myocarditis. 2005 , 78, 195-204	30
441	Simvastatin decreases myocardial tumor necrosis factor alpha content in heart transplant recipients. 2005 , 24, 46-51	28
440	Intracellular monocyte cytokine production and CD 14 expression are up-regulated in severe vs mild chronic heart failure. 2005 , 24, 854-9	26
439	Interaction between tumor necrosis factor-alpha and leptin-induced inhibition of cardiac contractile function in isolated ventricular myocytes. 2005 , 32, 213-8	8
438	Cardiac remodeling and failure: from molecules to man (Part I). 2005 , 14, 1-11	90
437	Upregulation of A2A adenosine receptor expression by TNF-alpha in PBMC of patients with CHF: a regulatory mechanism of inflammation. 2005 , 11, 67-73	34
436	Effects of different degrees of sympathetic antagonism on cytokine network in patients with ischemic dilated cardiomyopathy. 2005 , 11, 213-9	17

435	Mechanisms of cardiac hypertrophy. 2005 , 1, 263-73	18
434	Pro-Inflammatory Cytokines and Cardiac Extracellular Matrix: Regulation of Fibroblast Phenotype. 2005 , 57-81	4
433	Biological and Functional Effects of Chronic Mechanical Support Induced by Left Ventricular Assist Devices on Failing Human Myocardium. 2005 , 311-328	
432	Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis. 2005 , 7, R1227-34	35
431	Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis. 2005 , 7, 195-207	52
430	Cachexia in Cardiovascular Illness. 2006 , 349-361	1
429	Impact of atherosclerosis-related gene polymorphisms on mortality and recurrent events after myocardial infarction. 2006 , 185, 400-5	30
428	Biomarkers of Inflammation. 2006 , 295-318	
427	Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. 2006 , 48, 1217-24	427
426	Delayed death in burns and the allegations of medical negligence. 2006 , 32, 269-75	8
425	Cardiotrophin-1 induces interleukin-6 synthesis in human umbilical vein endothelial cells. 2006 , 36, 101-6	27
424	Type D personality is associated with increased levels of tumour necrosis factor (TNF)-alpha and TNF-alpha receptors in chronic heart failure. 2006 , 113, 34-8	84
423	Regulating the regulator: NF-kappaB signaling in heart. 2006 , 41, 580-91	148
422	Inhibition of prostaglandins does not reduce the cardiovascular changes during endotoxemia in rats. 2006 , 74, 135-42	6
421	Impaired expression of cardiac adiponectin in leptin-deficient mice with viral myocarditis. 2006 , 47, 107-23	28
420	In vitro endothelial cell activation and inflammatory responses in end-stage heart failure. 2006 , 101, 1466-73	7
419	Tumor-necrosis-factor-alpha-gene-deficient mice have improved cardiac function through reduction of intercellular adhesion molecule-1 in myocardial infarction. 2006 , 70, 1635-42	12
418	Association of hyperadiponectinemia with severity of ventricular dysfunction in congestive heart failure. 2006 , 70, 1557-62	68

417	Central neurotensin, alpha-melanocyte-stimulating hormone (alpha-MSH) is upregulated in patients with congestive heart failure. 2006 , 45, 429-34	12
416	Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. 2006 , 83, 754-9	715
415	Modulation of the phosphoinositide 3-kinase signaling pathway alters host response to sepsis, inflammation, and ischemia/reperfusion injury. 2006 , 25, 432-9	113
414	TNF gene polymorphisms are associated with reduced survival in severe Chagas' disease cardiomyopathy patients. 2006 , 8, 598-603	49
413	Systemic inflammation in heart failure--the whys and wherefores. 2006 , 11, 83-92	208
412	Inflammation, ECG changes and pericardial effusion: whom to biopsy in suspected myocarditis?. 2006 , 95, 569-83	25
411	Inflammatory biomarkers in heart failure. 2006 , 12, 324-8	54
410	Biomarkers for heart failure. 2006 , 21, 215-8	5
409	Comparative effects of pranidipine with amlodipine in rats with heart failure. 2006 , 77, 1-10	9
408	The tumor necrosis factor superfamily in heart failure. 2006 , 2, 101-11	10
407	Circulating levels of tumor necrosis factor-alpha correlate positively with severity of peripheral oedema in patients with right heart failure. 2006 , 8, 141-6	11
406	Blockade of NF-kappaB improves cardiac function and survival after myocardial infarction. 2006 , 291, H1337-44	117
405	Mechanisms leading to reversible mechanical dysfunction in severe CAD: alternatives to myocardial stunning. 2006 , 291, H2570-82	19
404	Activation of peroxisome proliferator-activated receptor-alpha and -gamma in auricular tissue from heart failure patients. 2006 , 8, 154-61	13
403	Electrical remodeling of cardiac myocytes from mice with heart failure due to the overexpression of tumor necrosis factor-alpha. 2006 , 290, H2098-107	78
402	Risk Factor Analysis of Plasma Cytokines in Patients With Coronary Artery Disease by a Multiplexed Fluorescent Immunoassay. 2006 , 125, 906-913	40
401	Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. 2007 , 12, 1124-33	107
400	Serum HER2 levels are increased in patients with chronic heart failure. 2007 , 9, 173-7	45

399	Soluble TNF receptors prevent apoptosis in infiltrating cells and promote ventricular rupture and remodeling after myocardial infarction. 2007 , 73, 794-805	27
398	Tumor necrosis factor-alpha reduces argininosuccinate synthase expression and nitric oxide production in aortic endothelial cells. 2007 , 293, H1115-21	83
397	Cardiomyocyte apoptosis is related to left ventricular dysfunction and remodelling in dilated cardiomyopathy, but is not affected by growth hormone treatment. 2007 , 9, 160-7	21
396	Effects of thalidomide treatment in heart failure patients. 2007 , 108, 237-42	13
395	Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. 2007 , 148, 3004-12	143
394	Cardiac remodeling and dysfunction in nephrotic syndrome. 2007 , 71, 1240-8	11
393	Does nitric oxide contribute to progressive cardiac tissue damage and dysfunction after infarction?. 2007 , 9, 757-63	2
392	Inhibition of PPAR-alpha activity in mice with cardiac-restricted expression of tumor necrosis factor: potential role of TGF-beta/Smad3. 2007 , 292, H1443-51	29
391	Myocardial structural changes in long-term human severe sepsis/septic shock may be responsible for cardiac dysfunction. 2007 , 27, 10-8	68
390	A model of myocardial inflammation and dysfunction in burn complicated by sepsis. 2007 , 28, 326-33	21
389	Melanocortin interventions in cachexia: how soon from bench to bedside?. 2007 , 10, 457-62	20
388	Insights from knock-out models concerning postischemic release of TNFalpha from isolated mouse hearts. 2007 , 42, 133-41	31
387	Reverse remodeling during long-term mechanical unloading of the left ventricle. 2007 , 43, 231-42	68
386	NO-cGMP and TNF-alpha counter regulatory system in blood: understanding the mechanisms leading to myocardial dysfunction and failure. 2007 , 1772, 5-14	22
385	Cardiotrophin-1 induces interleukin-6 synthesis in human monocytes. 2007 , 38, 137-44	25
384	Tumor necrosis factor-alpha alters calcium handling and increases arrhythmogenesis of pulmonary vein cardiomyocytes. 2007 , 80, 1806-15	82
383	Adenosine and TNF-alpha exert similar inotropic effect on heart cultures, suggesting a cardioprotective mechanism against hypoxia. 2007 , 81, 803-13	9
382	Cytokine activation and disease progression in patients with stable moderate chronic heart failure. 2007 , 26, 622-9	17

381	Nuclear factor-kappaB activity in peripheral blood mononuclear cells in cachectic and non-cachectic patients with chronic heart failure. 2007 , 122, 111-6	10
380	Functional capacity and changes in the neurohormonal and cytokine status after long-term CRT in heart failure patients. 2007 , 121, 68-73	25
379	Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. 2007 , 190, 1-9	193
378	Potential mechanisms of benefit with thalidomide in chronic heart failure. 2007 , 7, 127-34	5
377	TNF-alpha blockade decreases oxidative stress in the paraventricular nucleus and attenuates sympathoexcitation in heart failure rats. 2007 , 293, H599-609	93
376	Tumor necrosis factor-alpha is toxic via receptor 1 and protective via receptor 2 in a murine model of myocardial infarction. 2007 , 293, H743-53	103
375	Circulating levels of tumor necrosis factor receptors are highly predictive of mortality in patients with rheumatoid arthritis. 2007 , 56, 3940-8	30
374	Immune activation and inflammatory system in chronic heart failure: novel pathophysiological hypotheses generate new therapeutic options. 2007 , 61, 536-8	1
373	Relation between CD4+ T-cell activation and severity of chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. 2007 , 100, 483-8	29
372	Heart rate and arrhythmia in patients with psoriasis vulgaris. 2007 , 38, 64-9	34
371	Roles of cyclooxygenase-2 and phosphorylated Akt (Thr308) in cardiac hypertrophy regression mediated by left-ventricular unloading. 2007 , 133, 37-43	8
370	Cardiac cachexia at a glance. 2007 , 22, 101-3	2
369	Role of inflammation in the progression of heart failure. 2007 , 9, 236-41	139
368	P1 receptors and cytokine secretion. 2007 , 3, 13-25	50
367	High dose aspirin and left ventricular remodeling after myocardial infarction: aspirin and myocardial infarction. 2007 , 102, 334-40	14
366	Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. 2007 , 102, 500-7	151
365	A single intravenous sTNFR-Fc administration at the time of reperfusion limits infarct size--implications in reperfusion strategies in man. 2008 , 22, 437-42	8
364	Myocardial adaptations in the failing heart: cause or consequence?. 2008 , 29, 159-62	5

363	Effects of exercise training on inflammatory markers in patients with heart failure. 2008 , 13, 39-49	38
362	Proinflammatory cytokines in acute myocardial infarction with and without cardiogenic shock. 2008 , 97, 298-305	73
361	DNAzymes and cardiovascular disease. 2008 , 154, 741-8	18
360	Nuclear factor-kappaB inhibition improves myocardial contractility in rats with cirrhotic cardiomyopathy. 2008 , 28, 640-8	35
359	Positive correlation of tumor necrosis factor-alpha early expression in myocardium and ventricular arrhythmias in rats with acute myocardial infarction. 2008 , 39, 285-91	14
358	Anorexia, cachexia and nutrition. 2008 , 36, 78-81	7
357	Molecular and Cellular Phenotypes of Cardiovascular Aging. 2008 , 103-146	
356	The role of TNF-alpha receptors p55 and p75 in acute myocardial ischemia/reperfusion injury and late preconditioning. 2008 , 45, 735-41	36
355	Cytokines and myocardial dysfunction: state of the art. 2008 , 14, 61-74	74
354	Cardiac recovery during mechanical assist device support. 2008 , 20, 234-46	41
353	TNFalpha in patients with end-stage heart failure on medical therapy or supported by a left ventricular assist device. 2008 , 19, 64-8	15
352	Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. 2008 , 13, 1296-305	35
351	Wide spectrum of presentation and variable mechanisms of compromised cardiac function in multiple organ dysfunction syndrome. 2008 , 4, 239-248	3
350	Lower levels of the host protective IL-10 in DCM--a feature of autoimmune pathogenesis?. 2008 , 41, 478-83	10
349	Desmin mediates TNF-alpha-induced aggregate formation and intercalated disk reorganization in heart failure. 2008 , 181, 761-75	56
348	Prognostic value of apoptosis markers in advanced heart failure patients. 2009 , 30, 789-96	81
347	Device-based nonspecific immunomodulation therapy (Celacade), and its potential role in the treatment of chronic heart failure. 2008 , 16, 280-7	6
346	Morphological and molecular changes of the myocardium after left ventricular mechanical support. 2008 , 4, 157-69	27

345	Association of tumor necrosis factor-alpha with early target organ damage in newly diagnosed patients with essential hypertension. 2008 , 26, 2168-75	34
344	Cytokines and acute heart failure. 2008 , 36, S9-16	89
343	Cardiotrophin-1 induces intercellular adhesion molecule-1 expression by nuclear factor B activation in human umbilical vein endothelial cells. 2008 , 121, 2592-2598	10
342	Infliximab for the treatment of plaque psoriasis. 2008 , 2, 115-24	18
341	(1,3)-βGlucans in Innate Immunity. 2009 , 579-619	8
340	Angiotensin II downregulates the fatty acid oxidation pathway in adult rat cardiomyocytes via release of tumour necrosis factor-alpha. 2009 , 82, 341-50	51
339	Overview of emerging pharmacotherapy in chronic heart failure. 2009 , 10, 2055-74	4
338	Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. 2009 , 11, 342-8	97
337	TNF-alpha inhibition attenuates adverse myocardial remodeling in a rat model of volume overload. 2009 , 297, H1462-8	53
336	Cardiotrophin-1 induces tumor necrosis factor alpha synthesis in human peripheral blood mononuclear cells. 2009 , 2009, 489802	7
335	Cellular cardiomyoplasty: what have we learned?. 2009 , 17, 89-101	13
334	Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation. <i>Circulation</i> , 2009 , 119, 1386-97	16.7 192
333	Cardiac cachexia: a systematic overview. 2009 , 121, 227-52	244
332	TNF receptors differentially signal and are differentially expressed and regulated in the human heart. 2009 , 9, 2679-96	45
331	Qiliqiangxin regulates the balance between tumor necrosis factor-alpha and interleukin-10 and improves cardiac function in rats with myocardial infarction. 2009 , 260, 51-5	34
330	Acute Trypanosoma cruzi experimental infection induced renal ischemic/reperfusion lesion in mice. 2009 , 106, 111-20	14
329	[Heart failure in diabetes]. 2009 , 159, 134-40	0
328	Role of apoptosis in cardiovascular disease. 2009 , 14, 536-48	254

327	Circulating proinflammatory cytokines and N-terminal pro-brain natriuretic peptide significantly decrease with recovery of left ventricular function in patients with dilated cardiomyopathy. 2009 , 324, 139-45	11
326	Biology of TNFalpha and IL-10, and their imbalance in heart failure. 2009 , 14, 113-23	56
325	Reverse cardiac remodeling enabled by mechanical unloading of the left ventricle. 2009 , 2, 114-25	12
324	Diabetische Herzinsuffizienz. 2009 , 3, 20-24	
323	Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. 2009 , 5, 549-60	75
322	The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. 2009 , 409, 96-9	117
321	Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis. 2009 , 60, 225-30	61
320	PKC and MLCK-dependent, cytokine-induced rat coronary endothelial dysfunction. 2009 , 152, 76-83	29
319	Muscle wastage in heart failure: orphan of the heart failure. 2009 , 135, 233-6	5
318	Myocardial revascularization by left ventricular assisted beating heart is associated with reduced systemic inflammatory response. 2009 , 87, 46-52	37
317	Sex-based cardiac physiology. 2009 , 71, 1-18	99
316	The proinflammatory environment in potential heart and lung donors: prevalence and impact of donor management and hormonal therapy. 2009 , 88, 582-8	55
315	Tumor necrosis factor-alpha decreases sarcoplasmic reticulum Ca ²⁺ -ATPase expressions via the promoter methylation in cardiomyocytes. 2010 , 38, 217-22	107
314	Atrial fibrillation in congestive heart failure. 2010 , 18, 38-50	34
313	Improved cardiac performance by rosuvastatin is associated with attenuations in both myocardial tumor necrosis factor-alpha and p38 MAP kinase activity in rats after myocardial infarction. 2010 , 340, 121-7	7
312	[Biologics and cardiovascular risk]. 2010 , 69, 702-6, 708-11	
311	The effect of diazepam on myocardial function and coronary vascular tone after endotoxemia in the isolated rat heart model. 2010 , 59, 907-13	9
310	TNF-alpha modulates the migratory response of mesenchymal stem cells to TRAIL. 2010 , 67, 1307-14	17

309	Plasma levels of tumor necrosis factor-alpha and its receptors in patients with mitral stenosis and sinus rhythm undergoing percutaneous balloon valvuloplasty. 2010 , 25, 131-7	7
308	Dichotomous actions of NF-kappaB signaling pathways in heart. 2010 , 3, 344-54	25
307	Decreased myocardial expression of dystrophin and titin mRNA and protein in dilated cardiomyopathy: possibly an adverse effect of TNF-alpha. 2010 , 30, 520-30	6
306	Biomarkers of inflammation in heart failure. 2010 , 15, 331-41	153
305	Microglia activation in the hypothalamic PVN following myocardial infarction. 2010 , 1326, 96-104	63
304	TNF-alpha-mediated signal transduction pathway is a major determinant of apoptosis in dilated cardiomyopathy. 2010 , 14, 1988-97	13
303	Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor Fn14 during cardiac remodelling in rats. 2010 , 199, 11-22	36
302	Lung dysfunction following cardiopulmonary bypass. 2010 , 25, 47-55	167
301	Apoptosis in cardiovascular diseases: mechanism and clinical implications. 2010 , 40, 299-305	71
300	Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin. 2010 , 107, 14357-62	45
299	Multiple cytokine biomarkers in heart failure. 2010 , 10, 147-57	16
298	Targeting the vicious inflammation-oxidative stress cycle for the management of heart failure. 2010 , 13, 1033-49	115
297	Monocytes in heart failure: relationship to a deteriorating immune overreaction or a desperate attempt for tissue repair?. 2010 , 85, 649-60	57
296	Separate mechanisms cause anemia in ischemic vs. nonischemic murine heart failure. 2010 , 298, R808-14	12
295	Role of the hypothalamic PVN in the regulation of renal sympathetic nerve activity and blood flow during hyperthermia and in heart failure. 2010 , 298, F839-46	51
294	Whole grape intake impacts cardiac peroxisome proliferator-activated receptor and nuclear factor kappaB activity and cytokine expression in rats with diastolic dysfunction. 2010 , 55, 1179-85	42
293	Assessment of the potential heart donor: a role for biomarkers?. 2010 , 56, 352-61	23
292	Evaluation of right ventricle function in children with primary nephrotic syndrome. 2010 , 51, 166-71	2

291	Short-term mechanical unloading and reverse remodeling of failing hearts in children. 2010 , 29, 98-104	21
290	Mechanisms of TNF α -induced cardiac dysfunction in cholestatic bile duct-ligated mice: interaction between TNF α and endocannabinoids. 2010 , 53, 298-306	61
289	Serum YKL-40 predicts adverse clinical outcomes in patients with chronic heart failure. 2010 , 16, 873-9	31
288	Obesity and survival in patients with heart failure and preserved systolic function: a U-shaped relationship. 2010 , 159, 75-80	100
287	Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. 2010 , 160, 487.e1-7	111
286	Serum albumin and mortality in acutely decompensated heart failure. 2010 , 160, 1149-55	122
285	NSAIDs and Cardiovascular Toxicity. 2010 , 323-336	
284	Consequences of chronic inflammation in peritoneal dialysis. 2011 , 31, 159-71	27
283	ROS signalling of inflammatory cytokines during Trypanosoma cruzi infection. 2011 , 76, 153-70	35
282	Hormonal Mechanisms of Cardiac Remodeling in Heart Failure. 2011 , 215-229	1
281	Toll-like receptors: new players in myocardial ischemia/reperfusion injury. 2011 , 15, 1875-93	84
280	TNF- α increases cardiac fibroblast lysyl oxidase expression through TGF- β and PI3Kinase signaling pathways. 2011 , 413, 370-5	52
279	CD34+ cell mobilization and upregulation of myocardial cytokines in a rabbit model of myocardial ischemia. 2011 , 152, 18-23	10
278	Insulin treatment of diabetic rats reduces cardiac function in a lipopolysaccharide-induced systemic inflammation model. 2011 , 171, 251-8	1
277	Activation of Inflammatory Mediators in Heart Failure. 2011 , 163-184	1
276	Alterations in Nutrition and Body Mass in Heart Failure. 2011 , 330-345	
275	Association of IL1B polymorphism with left ventricular systolic dysfunction: a relation with the release of interleukin-1 β in stress condition. 2011 , 21, 579-86	5
274	Systems biology of heart failure, challenges and hopes. 2011 , 26, 314-21	12

273	Communication signals between cardiac fibroblasts and cardiac myocytes. 2011 , 57, 513-21	38
272	Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome. 2011 , 32, 1390-7	22
271	Nox2 and Nox4 mediate tumour necrosis factor- α -induced ventricular remodelling in mice. 2011 , 15, 2601-13	19
270	TNF α in myocardial ischemia/reperfusion, remodeling and heart failure. 2011 , 16, 49-69	175
269	Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. 2011 , 16, 13-21	168
268	Luteolin prevents LPS-induced TNF α -expression in cardiac myocytes through inhibiting NF- κ B signaling pathway. 2011 , 34, 620-9	24
267	Serum concentrations of interleukin-4 and interferon-gamma in relation to severe left ventricular dysfunction in patients with acute myocardial infarction undergoing percutaneous coronary intervention. 2011 , 26, 399-407	20
266	Cardio-renal cachexia syndromes (CRCS): pathophysiological foundations of a vicious pathological circle. 2011 , 2, 135-142	24
265	Immune modulation in heart failure: past challenges and future hopes. 2011 , 8, 28-37	20
264	Stromal vascular fraction transplantation as an alternative therapy for ischemic heart failure: anti-inflammatory role. 2011 , 6, 43	64
263	Follistatin-like 1 in chronic systolic heart failure: a marker of left ventricular remodeling. 2011 , 4, 621-7	50
262	Altered desmosomal proteins in granulomatous myocarditis and potential pathogenic links to arrhythmogenic right ventricular cardiomyopathy. 2011 , 4, 743-52	122
261	The cell biology of disease: cellular mechanisms of cardiomyopathy. 2011 , 194, 355-65	231
260	Metabolic syndrome, chronic kidney, and cardiovascular diseases: role of adipokines. 2011 , 2011, 653182	41
259	Qililiqiangxin affects L type Ca^{2+} current in the normal and hypertrophied rat heart. 2012 , 2012, 131830	8
258	Effect of bisphenol A on the myocardium of adult male albino rats and the possible role of lycopene. 2012 , 35, 326-339	3
257	Septic cardiomyopathy. 2012 , 50, 187-201	4
256	Renal failure in association with thermal injuries. 2012 , 369-376.e3	2

255	Exercise training leads to a reduction of elevated myostatin levels in patients with chronic heart failure. 2012 , 19, 404-11	86
254	Mathematical modeling mechanisms of arrhythmias in transgenic mouse heart overexpressing TNF- α 2012 , 302, H934-52	20
253	The use of ghrelin and ghrelin receptor agonists as a treatment for animal models of disease: efficacy and mechanism. 2012 , 18, 4779-99	17
252	Chronic intermittent hypoxia exposure improves left ventricular contractility in transgenic mice with heart failure. 2012 , 113, 791-8	21
251	Estrogenic modulation of inflammation-related genes in male rats following volume overload. 2012 , 44, 362-73	5
250	Cardiac intercellular communication: are myocytes and fibroblasts fair-weather friends?. 2012 , 5, 768-82	40
249	The methionine 196 arginine polymorphism of the TNF receptor 2 gene (TNFRSF1B) is not associated with worse outcomes in heart failure. 2012 , 60, 838-42	4
248	TNF- α myocardial perfusion and function in patients with ST-segment elevation myocardial infarction and primary percutaneous coronary intervention. 2012 , 101, 815-27	20
247	Differential expression of caveolin-1 and caveolin-3: potential marker for cardiac toxicity subsequent to chronic ozone inhalation. 2012 , 369, 9-15	5
246	High-frequency ultrasound evaluation of effects of early treatment with metoprolol on myocardial inflammatory cytokine expression in rats with acute myocardial infarction. 2012 , 32, 774-778	4
245	The heart-protective mechanism of nitronyl nitroxide radicals on murine viral myocarditis induced by CVB3. 2012 , 94, 1951-9	8
244	The role of inflammation in the cardio-renal syndrome: a focus on cytokines and inflammatory mediators. 2012 , 32, 70-8	61
243	TNF revisited: osteoprotegerin and TNF-related molecules in heart failure. 2012 , 9, 92-100	22
242	Interleukin-6, -7, -8 and -10 predict outcome in acute myocardial infarction complicated by cardiogenic shock. 2012 , 101, 375-84	70
241	NADPH oxidase-dependent oxidative stress in the failing heart: From pathogenic roles to therapeutic approach. 2012 , 52, 291-7	62
240	A 21st century evaluation of the safety of oral vitamin D. 2012 , 28, 344-56	29
239	LPS induces cardiomyocyte injury through calcium-sensing receptor. 2013 , 379, 153-9	26
238	The effects of endothelial lipase gene (LIPG) variants on inflammation marker levels and atherosclerosis development. 2013 , 40, 5143-9	5

237	Attenuation of monocyte chemotaxis--a novel anti-inflammatory mechanism of action for the cardio-protective hormone B-type natriuretic peptide. 2013 , 6, 545-57	18
236	P2Y2 receptor agonist with enhanced stability protects the heart from ischemic damage in vitro and in vivo. 2013 , 9, 633-42	27
235	How can we cure a heart "in flame"? A translational view on inflammation in heart failure. 2013 , 108, 356	77
234	Nonthyroidal illness and the cardiorenal syndrome. 2013 , 9, 599-609	30
233	[Obesity and cardiac cachexia in chronic heart failure]. 2013 , 38, 610-7	3
232	Protein engineering for cardiovascular therapeutics: untapped potential for cardiac repair. 2013 , 113, 933-43	38
231	Effects of 50 Hz extremely low frequency sinusoidal magnetic fields on the apoptosis of the hearts of preincubated chicken embryos at different levels of developments. 2013 , 89, 234-42	2
230	Treatment of cachexia: melanocortin and ghrelin interventions. 2013 , 92, 197-242	12
229	Is it safe to use TNF- α blockers for systemic inflammatory disease in patients with heart failure? Importance of dosage and receptor specificity. 2013 , 167, 1719-23	9
228	An inverse correlation between TNF alpha serum levels and heart rate variability in patients with heart failure. 2013 , 62, 37-43	25
227	Role of cytochrome P450-mediated arachidonic acid metabolites in the pathogenesis of cardiac hypertrophy. 2013 , 45, 173-95	34
226	The effect of vitamin D status on risk factors for cardiovascular disease. 2013 , 9, 337-47	69
225	Contributions of cardiomyocyte-cardiac fibroblast-immune cell interactions in heart failure development. 2013 , 108, 357	47
224	Macrophage Activation Syndrome in a Patient With Adult Still's Disease Following Rituximab: Presenting With Pseudo-Septic Shock 2013 , 4, 248-251	2
223	The effect of normovolemic modified ultrafiltration on inflammatory mediators, endotoxins, terminal complement complexes and clinical outcome in high-risk cardiac surgery patients. 2013 , 28, 306-14	26
222	Erectile dysfunction in heart failure patients: a critical reappraisal. 2013 , 1, 177-91	16
221	Association of tumor necrosis factor- α gene G-308A polymorphism with dilated cardiomyopathy: a meta-analysis. 2013 , 32, 130-7	8
220	Relationship between inflammation and microalbuminuria in prehypertension. 2013 , 27, 119-25	16

219	Evaluating Chagas disease progression and cure through blood-derived biomarkers: a systematic review. 2013 , 11, 957-76	36
218	Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure. 2013 , 14, 49-56	4
217	The physiology of cardiovascular disease and innovative liposomal platforms for therapy. 2013 , 8, 629-40	18
216	Urokinase plasminogen activator induces pro-fibrotic/m2 phenotype in murine cardiac macrophages. 2013 , 8, e57837	25
215	Inflammation and prolonged QT time: results from the Cardiovascular Disease, Living and Ageing in Halle (CARLA) study. 2014 , 9, e95994	24
214	Role of exercise training on autonomic changes and inflammatory profile induced by myocardial infarction. 2014 , 2014, 702473	11
213	Neopterin and beta-2 microglobulin relations to immunity and inflammatory status in nonischemic dilated cardiomyopathy patients. 2014 , 2014, 585067	4
212	Immunopathological aspects of experimental <i>Trypanosoma cruzi</i> reinfections. 2014 , 2014, 648715	9
211	Inflammation and echocardiographic parameters of ventricular hypertrophy in a cohort with preserved cardiac function. 2014 , 1, e000004	10
210	Antibodies against potassium channel interacting protein 2 induce necrosis in isolated rat cardiomyocytes. 2014 , 115, 678-89	2
209	Cardiovascular risk and the use of biologic agents in rheumatoid arthritis. 2014 , 16, 459	8
208	Cerebral blood flow velocity and vasomotor reactivity during autonomic challenges in heart failure. 2014 , 63, 194-202	7
207	Statin-mediated low-density lipoprotein lowering in chronic congestive heart failure. 2014 , 347, 14-22	4
206	TWEAK-Fn14 Cytokine-Receptor Axis: A New Player of Myocardial Remodeling and Cardiac Failure. <i>Frontiers in Immunology</i> , 2014 , 5, 50	8.4 29
205	Contribution of ventricular assist devices to the recovery of failing hearts: a review and the Berlin Heart Center Experience. 2014 , 16, 248-63	27
204	Modulation of cardiac cytochrome P450 in patients with heart failure. 2014 , 10, 327-39	11
203	Pacing-induced cardiomyopathy: pathophysiological insights through matrix metalloproteinases. 2014 , 19, 669-80	8
202	A direct link between haemodynamic failure and inflammatory activation in heart failure: the simplified approach to heart failure and to creation of life. 2014 , 35, 413-5	2

201	Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox. 2014 , 14, 387-92	7
200	Signal transducers and activators of transcription (STATs) gene polymorphisms related with susceptibility to rheumatic heart disease in north Indian population. 2014 , 161, 100-5	8
199	Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. 2014 , 19, 681-94	104
198	Recent insights on the molecular mechanisms and therapeutic approaches for cardiac cachexia. 2014 , 47, 8-15	31
197	Hypoalbuminemia in acute heart failure patients: causes and its impact on hospital and long-term mortality. 2014 , 20, 350-8	85
196	The pathogenesis of cardiac fibrosis. 2014 , 71, 549-74	837
195	Up-regulated TLR4 in cardiomyocytes exacerbates heart failure after long-term myocardial infarction. 2015 , 19, 2728-40	95
194	Cell Death in the Cardiac Myocyte. 2015 , 38, 1094-7	23
193	Decreased circulating and neutrophil mediated VEGF-A165 release in stable long-term cardiac transplant recipients. 2015 , 7, 4	1
192	The case for inhibiting p38 mitogen-activated protein kinase in heart failure. <i>Frontiers in Pharmacology</i> , 2015 , 6, 102	5.6 44
191	Inflammatory Biomarkers in Refractory Congestive Heart Failure Patients Treated with Peritoneal Dialysis. 2015 , 2015, 590851	6
190	The tumor necrosis factor-β238G/A and IL-6 -572G/C gene polymorphisms and the risk of idiopathic dilated cardiomyopathy: a meta-analysis of 25 studies including 9493 cases and 13,971 controls. 2015 , 53, 307-18	6
189	Effect of coenzyme Q10 on the incidence of atrial fibrillation in patients with heart failure. 2015 , 63, 735-9	19
188	The role of TNF-α/Fas/Fas ligand system and NT-proBNP in the early detection of asymptomatic left ventricular dysfunction in cancer patients treated with anthracyclines. 2015 , 6, 85-90	1
187	Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. 2015 , 89, 1401-38	337
186	Epigenetics of the failing heart. 2015 , 20, 435-59	14
185	Tumor necrosis factor alpha stimulates p62 accumulation and enhances proteasome activity independently of ROS. 2015 , 31, 83-94	19
184	Erectile Dysfunction in Coronary Artery Disease and Heart Failure. 2015 , 59-71	2

183	Innate immunity and the failing heart: the cytokine hypothesis revisited. 2015 , 116, 1254-68	375
182	Influence of psoriasis on circulatory system function assessed in echocardiography. 2015 , 307, 855-61	10
181	Dual Activation of TRIF and MyD88 Adaptor Proteins by Angiotensin II Evokes Opposing Effects on Pressure, Cardiac Hypertrophy, and Inflammatory Gene Expression. 2015 , 66, 647-56	37
180	Molecular identity of the mitochondrial permeability transition pore and its role in ischemia-reperfusion injury. 2015 , 78, 142-53	154
179	Methanolic Extract of Ceplukan Leaf (<i>Physalis minima</i> L.) Attenuates Ventricular Fibrosis through Inhibition of TNF- α in Ovariectomized Rats. 2016 , 2016, 2428052	1
178	TNF Affects Ciliary Beat Response to Increased Viscosity in Human Pediatric Airway Epithelium. 2016 , 2016, 3628501	4
177	Caffeoylquinic Acid Derivatives Extract of <i>Erigeron multiradiatus</i> Alleviated Acute Myocardial Ischemia Reperfusion Injury in Rats through Inhibiting NF-KappaB and JNK Activations. 2016 , 2016, 7961940	12
176	Inflammation and thrombosis - testing the hypothesis with anti-inflammatory drug trials. 2016 , 116, 1012-1021	30
175	Pathophysiology of Heart Failure and an Overview of Therapies. 2016 , 271-339	1
174	The Coexistence of Hypertension and Ovariectomy Additively Increases Cardiac Apoptosis. 2016 , 17,	13
173	Effects of Synthetic Anti-Inflammatory Sterol in CB3V-Induced Myocarditis: A Morphological Study on Heart Muscle Tissue. 2016 , 1, 69-89	7
172	Cardiac Troponin and Tropomyosin: Structural and Cellular Perspectives to Unveil the Hypertrophic Cardiomyopathy Phenotype. 2016 , 7, 429	19
171	Correlations between MTP and ROS Levels of Peripheral Blood Lymphocytes and Readmission in Patients with Chronic Heart Failure. 2016 , 25, 296-302	9
170	Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle Disorders. 2016 , 68, 476-532	233
169	Impact of Cellular Mechanisms of Ischemia on CABG Failure. 2016 , 351-391	2
168	Transcriptional patterns of reverse remodeling with left ventricular assist devices: a consistent signature. 2016 , 13, 1029-1034	5
167	Subclinical cardiovascular disease and it's improvement after long-term TNF- α inhibitor therapy in severe psoriatic patients. 2016 , 30, 1531-6	12
166	Primary skeletal muscle myoblasts from chronic heart failure patients exhibit loss of anti-inflammatory and proliferative activity. 2016 , 16, 107	9

165	Risk stratification based on nutritional screening on admission: Three-year clinical outcomes in hospitalized patients with acute heart failure syndrome. 2016 , 68, 392-398	14
164	Tumor necrosis factor- α impairs adiponectin signalling, mitochondrial biogenesis, and myogenesis in primary human myotubes cultures. 2016 , 310, H1164-75	23
163	Effect of metformin and sitagliptin on doxorubicin-induced cardiotoxicity in adult male albino rats. 2016 , 35, 1227-1239	18
162	Cardioprotection mechanism of mangiferin on doxorubicin-induced rats: Focus on intracellular calcium regulation. 2016 , 54, 1289-97	17
161	Inflammatory biomarkers and effect of exercise on functional capacity in patients with heart failure: Insights from a randomized clinical trial. 2017 , 24, 808-817	20
160	Orosomucoid as prognosis factor associated with inflammation in acute or nutritional status in chronic heart failure. 2017 , 228, 488-494	9
159	The selective estrogen receptor modulators (SERMs) raloxifene and tamoxifen improve ANP levels and decrease nuclear translocation of NF- κ B in estrogen-deficient rats. 2017 , 69, 798-805	7
158	Skeletal muscle alterations in HFrEF vs. HFpEF. 2017 , 14, 489-497	19
157	Proinflammatory Cytokines Mediate GPCR Dysfunction. 2017 , 70, 61-73	8
156	Apoptosis in ischemic heart disease. 2017 , 15, 87	110
155	Inflammation - Cause or Consequence of Heart Failure or Both?. 2017 , 14, 251-265	211
154	Anti-fibrotic Potential of AT Receptor Agonists. <i>Frontiers in Pharmacology</i> , 2017 , 8, 564	5.6 41
153	TNF α Modulates Cardiac Conduction by Altering Electrical Coupling between Myocytes. 2017 , 8, 334	19
152	Cardiac Immunomodulation. 2017 , 681-714	1
151	Identification of the difference in the pathogenesis in heart failure arising from different etiologies using a microarray dataset. 2017 , 72, 600-608	7
150	Insights from Second-Line Treatments for Idiopathic Dilated Cardiomyopathy. 2017 , 4,	2
149	Involvement of Cytokines in the Pathogenesis of Salt and Water Imbalance in Congestive Heart Failure. <i>Frontiers in Immunology</i> , 2017 , 8, 716	8.4 11
148	Pro-Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction. 2018 , 7,	22

147	Immune Modulation in Heart Failure: the Promise of Novel Biologics. 2018 , 20, 26	10
146	Preoperative Nutritional Assessment with the Prognostic Nutrition Index in Patients Undergoing Left Ventricular Assist Device Implantation. 2018 , 64, 52-55	23
145	Shed-blood-separation and cell-saver: an integral Part of MiECC? Shed-blood-separation and its influence on the perioperative inflammatory response during coronary revascularization with minimal invasive extracorporeal circulation systems - a randomized controlled trial. 2018 , 33, 136-147	14
144	SDF-1 induces TNF-mediated apoptosis in cardiac myocytes. 2018 , 23, 79-91	30
143	Temporal Frame of Immune Cell Infiltration during Heart Failure Establishment: Lessons from Animal Models. 2018 , 19,	9
142	Tumor Necrosis Factor- α in Heart Failure: an Updated Review. 2018 , 20, 117	48
141	Roles of apoptosis and inflammation in a rat model of acute lung injury induced right ventricular dysfunction. 2018 , 108, 1105-1114	3
140	Inflammation in Right Ventricular Failure: Does It Matter?. 2018 , 9, 1056	19
139	Association between rs1800629 polymorphism in tumor necrosis factor- α gene and dilated cardiomyopathy susceptibility: Evidence from case-control studies. 2018 , 97, e13386	3
138	Acute Renal Failure in Association with Thermal Injury. 2018 , 318-327.e2	1
137	Alcohol-Mediated Organ Damages: Heart and Brain. <i>Frontiers in Pharmacology</i> , 2018 , 9, 81	5.6 27
136	NSAIDs and Cardiovascular Toxicity. 2018 , 341-355	
135	Role of cytokines and inflammation in heart function during health and disease. 2018 , 23, 733-758	109
134	Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities. 2019 , 65, 70-99	284
133	Cardiomyopathy Associated with Diabetes: The Central Role of the Cardiomyocyte. 2019 , 20,	40
132	The Quest for Antiinflammatory and Immunomodulatory Strategies in Heart Failure. 2019 , 106, 1198-1208	9
131	Subacute Toxicity of Ethanolic Extract in Mice. 2019 , 35, 233-239	9
130	Cytokines in heart failure. 2019 , 93, 63-113	8

129	Bidirectional Relationship Between Cancer and Heart Failure: Old and New Issues in Cardio-oncology. 2019 , 5, 106-111	17
128	Embryonic stem cell-derived exosomes inhibit doxorubicin-induced TLR4-NLRP3-mediated cell death-pyroptosis. 2019 , 317, H460-H471	54
127	Transcript levels for extracellular matrix proteins are altered in MK5-deficient cardiac ventricular fibroblasts. 2019 , 132, 164-177	5
126	Right ventricular failure following left ventricular assist device implantation is associated with a preoperative pro-inflammatory response. 2019 , 14, 80	9
125	Advanced Evolution of Pathogenesis Concepts in Cardiomyopathies. 2019 , 8,	11
124	Phase II clinical trial testing the safety of a humanised monoclonal antibody anti-CD20 in patients with heart failure with reduced ejection fraction, ICFer-RITU2: study protocol. 2019 , 9, e022826	8
123	Skeletal Muscle Fatigability in Heart Failure. 2019 , 10, 129	17
122	Neopterin is Associated with Disease Severity and Outcome in Patients with Non-Ischaemic Heart Failure. 2019 , 8,	7
121	Role of Innate Immunity in Heart Failure. 2020 , 103-114.e2	
120	Inflammation in myocardial disease: From myocarditis to dilated cardiomyopathy. 2020 , 70, 1-11	32
119	Reappraisal of Inflammatory Biomarkers in Heart Failure. 2020 , 17, 9-19	9
118	Complexity of TNF- β Signaling in Heart Disease. 2020 , 9,	19
117	Effect of high-intensity interval training on cardiac structure and function in rats with acute myocardial infarct. 2020 , 131, 110690	2
116	The molecular mechanisms associated with the physiological responses to inflammation and oxidative stress in cardiovascular diseases. 2020 , 12, 947-968	16
115	Effect of Renal Denervation on Cardiac Function and Inflammatory Factors in Heart Failure After Myocardial Infarction. 2020 , 76, 602-609	1
114	Therapeutic Applications of Cannabinoids in Cardiomyopathy and Heart Failure. 2020 , 2020, 4587024	6
113	Differentially expressed lnc-NOS2P3-miR-939-5p axis in chronic heart failure inhibits myocardial and endothelial cells apoptosis via iNOS/TNF β pathway. 2020 , 24, 11381-11396	6
112	Prognostic utility of quantitative offline 2D-echocardiography in hospitalized patients with COVID-19 disease. 2020 , 37, 2029-2039	22

111	Ischemia reperfusion injury provokes adverse left ventricular remodeling in dysferlin-deficient hearts through a pathway that involves TIRAP dependent signaling. 2020 , 10, 14129	1
110	Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure. 2020 , 34, 849-863	47
109	The role of B cells in heart failure and implications for future immunomodulatory treatment strategies. 2020 , 7, 1387-1399	14
108	Secreted Phospholipase A-IIA Modulates Transdifferentiation of Cardiac Fibroblast through EGFR Transactivation: An Inflammation-Fibrosis Link. 2020 , 9,	7
107	Ibutilast, a Phosphodiesterase Inhibitor and Toll-Like Receptor-4 Antagonist, Improves Hemorrhagic Shock and Reperfusion-Induced Left Ventricular Dysfunction by Reducing Myocardial Tumor Necrosis Factor α 2020 , 52, 1869-1874	2
106	Reappraising the role of inflammation in heart failure. 2020 , 17, 269-285	138
105	Cancer Risk in the Heart Failure Population: Epidemiology, Mechanisms, and Clinical Implications. 2020 , 23, 7	6
104	Stress hyperglycemia, cardiac glucotoxicity, and critically ill patient outcomes current clinical and pathophysiological evidence. 2021 , 9, e14713	1
103	Diverse origins and activation of fibroblasts in cardiac fibrosis. 2021 , 78, 109869	6
102	Mortal Interaction Between Hemophagocytic Syndrome and Newly Developed Heart Failure. 2021 , 116, 395-401	1
101	Functional and molecular effects of TNF- α on human iPSC-derived cardiomyocytes. 2021 , 52, 102218	3
100	Upregulation of COX-2 and PGE Induced by TNF- α Mediated Through TNFR1/MitoROS/PKC β /P38 MAPK, JNK1/2/FoxO1 Cascade in Human Cardiac Fibroblasts. 2021 , 14, 2807-2824	3
99	Cell Death and Exosomes Regulation After Myocardial Infarction and Ischemia-Reperfusion. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 673677	5.7 7
98	Effects of intravenous furosemide plus small-volume hypertonic saline solutions on markers of heart failure. 2021 , 8, 4174-4186	1
97	Glucocorticoid-Induced Leucine Zipper (GILZ) in Cardiovascular Health and Disease. 2021 , 10,	1
96	Serum Soluble Tumor Necrosis Factor Receptors 1 and 2 Are Early Prognosis Markers After ST-Segment Elevation Myocardial Infarction. <i>Frontiers in Pharmacology</i> , 2021 , 12, 656928	5.6 0
95	[Effect of omega-3 fatty acids on hypoalbuminemia in acute heart failure patients with increased inflammatory activity]. 2021 , 38, 890-896	
94	Role of Nitric Oxide in the Pathophysiology of Heart Failure. 2004 , 81-92	1

93	Inflammatory cardiomyopathy: there is a specific matrix destruction in the course of the disease. 2006 , 219-50	8
92	Anti-viral treatment in patients with virus-induced cardiomyopathy. 2006 , 323-42	1
91	Recent Insights into the Role of Tumor Necrosis Factor in the Failing Heart. 2001 , 3-12	1
90	Vagal Nerve Stimulation for the Treatment of Heart Failure. 2017 , 157-179	1
89	Treatment of Rheumatoid Arthritis: Tumor Necrosis Factor Inhibitors. 2009 , 337-349	2
88	An overview of tumor necrosis factor alpha and the failing human heart. 1999 , 14, 206-10	68
87	Insights into the pathogenesis of chronic heart failure: immune activation and cachexia. 1999 , 14, 211-6	79
86	Myocardial depression versus myocardial destruction: integrating the multiple mechanisms of myocardial dysfunction during sepsis. 2000 , 28, 3111-2	13
85	Regulating cardiac cytokine expression: the role of the adrenergic nervous system. 2000 , 28, 3754-5	1
84	Neurohormonal Activation and Progression of Heart Failure. 1998 , 32, S16-S21	27
83	Neurohormonal Activation, Oxygen Free Radicals, and Apoptosis in the Pathogenesis of Congestive Heart Failure. 1998 , 32, S22-S30	146
82	Growth hormone-induced reduction of soluble apoptosis mediators is associated with reverse cardiac remodelling and improvement of exercise capacity in patients with idiopathic dilated cardiomyopathy. 2005 , 12, 164-168	11
81	Increased de novo ceramide synthesis and accumulation in failing myocardium. 2017 , 2,	42
80	Role of nitric oxide and peroxynitrite in the cytokine-induced sustained myocardial dysfunction in dogs in vivo. 1998 , 101, 2207-14	84
79	Risk factor analysis of plasma cytokines in patients with coronary artery disease by a multiplexed fluorescent immunoassay. 2006 , 125, 906-13	17
78	Lack of chemokine signaling through CXCR5 causes increased mortality, ventricular dilatation and deranged matrix during cardiac pressure overload. 2011 , 6, e18668	21
77	Pentosan polysulfate decreases myocardial expression of the extracellular matrix enzyme ADAMTS4 and improves cardiac function in vivo in rats subjected to pressure overload by aortic banding. 2014 , 9, e89621	25
76	Inflammation and renal function after a four-year follow-up in subjects with unimpaired glomerular filtration rate: results from the observational, population-based CARLA cohort. 2014 , 9, e108427	10

75	Relationship between exercise intolerance and levels of neurohormonal factors and proinflammatory cytokines in patients with stable chronic heart failure. 2005 , 46, 1049-59	18
74	Endothelin-1 concentrations in pericardial fluid are more elevated in patients with ischemic heart disease than in patients with nonischemic heart disease. 2003 , 44, 633-44	17
73	The Role of TNF- α as a Proinflammatory Cytokine in Pathological Processes. 2019 , 13, 332-338	10
72	The effect of cardiovascular drugs on pro-inflammatory cytokine secretion and natural killer activity of peripheral blood mononuclear cells of patients with chronic heart failure in vitro. 2007 , 10, 1580-7	2
71	Polymorphisms of tumor necrosis factor-alpha and interleukin-6 gene and C-reactive protein profiles in patients with idiopathic dilated cardiomyopathy. 2014 , 34, 407-14	9
70	Relationship between site of myocardial infarction, left ventricular function and cytokine levels in patients undergoing coronary artery surgery. 2016 , 27, 299-306	5
69	The Role of Neurohormonal Systems, Inflammatory Mediators and Oxydative Stress in Cardiomyopathy.	0
68	Akute kardiale Dyspnoe und Lungenödem. 2000 , 527-538	
67	The Heart Failure Syndrome: New Insights - From Receptors to Molecular Biology. 2000 , 1-18	
66	Mitral Valve repair for surgical remodeling. 2000 , 83-95	1
65	Neurohormones in Advanced Heart Failure. 2000 , 3-23	
64	Pathophysiologie der chronischen Herzinsuffizienz. 2000 , 545-595	
63	Klinik und Symptomatologie der chronischen Herzinsuffizienz. 2000 , 597-610	
62	Role of Oxidative Stress, Cytokines, and Apoptosis in Myocardial Dysfunction. 2000 , 193-209	
61	Definition und Epidemiologie der chronischen Herzinsuffizienz. 2000 , 539-543	
60	The Role of Interleukin-6 in the Failing Heart. 2001 , 27-34	0
59	The Effect of Cytokines on Cardiac Allograft Function: Tumor Necrosis Factor- α A Mediator of Chronic Injury. 2001 , 77-81	
58	The Role of Anti-Cytokine Therapy in the Failing Heart. 2001 , 83-91	

- 57 The clinical experience with anti-cytokine therapy in heart failure. **2003**, 95-110
- 56 Immunomodulation in Heart Failure: Experimental Models. **2003**, 203-219
- 55 Myocardial nitric oxide in cardiac remodeling. **2003**, 155-170
- 54 Cardiac Failure. **2005**, 221-231
- 53 Patients with dilated cardiomyopathy possess insulin resistance independently of cardiac dysfunction or serum tumor necrosis factor-alpha. **2006**, 47, 877-87 3
- 52 Renal failure in association with thermal injuries. **2007**, 446-453
- 51 Customizing Dietary Recommendations By Genotype In The Era Of Genomics. **2008**, 155-171
- 50 Synthetic Thyroid Hormone and Thyroid Hormone Analogues for Treatment of Heart Failure. **2009**, 225-241
- 49 Heart Failure and Changes at the Periphery: Vascular, Inflammation, Neurohormonal, and Renal Systems. **2010**, 235-255
- 48 Animal Models of Heart Failure. **2010**, 109-127
- 47 Antiviral interferon- α treatment in patients with chronic viral cardiomyopathy. **2010**, 265-278
- 46 Cytokine Profiles in Cardiac Diseases and Marrow Stromal Cells Therapy. **2013**, 421-425
- 45 Role of Toll-Like Receptors in Myocardial Ischemia/Reperfusion Injury. **2013**, 123-142
- 44 A Mechanism for Inhaled Anesthetic-Induced Solid Organ Injury: Inflammation. **2014**, 04, 72-80
- 43 Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. **1998**, 32 Suppl 1, S22-30 11
- 42 Neurohumoral activation and progression of heart failure: hypothetical and clinical considerations. **1998**, 32 Suppl 1, S16-21 3
- 41 3.?????????. **1998**, 87, 69-76
- 40 Entzündliche Herzmuskelerkrankung. **1998**, 111-146 5

- 39 Role of Nitric Oxide in the Regulation of Cardiovascular Performance: Clinical Implications for Sepsis and Congestive Heart Failure. **1999**, 119-143
- 38 Molecular Pathways and Animal Models of Cardiomyopathies. **2016**, 687-711
- 37 Heart Failure with Normal Left Ventricular Ejection Fraction (HFNEF). **2017**, 273-339
- 36 Relevance of Neutrophil Neprilysin in Heart Failure. **2021**, 10, 1
- 35 Guiding principles for cardiology care in times of the COVID-19 Pandemic: Gazing through the crystal ball. **2020**, 23, 532-536 1
- 34 Chronische Herzinsuffizienz. **2006**, 217-335
- 33 Molecular Mechanisms of Myocardial Remodeling. **1999**, 29-42 1
- 32 Death receptors and their ligands. **2000**, 5-28
- 31 Cardiac myocytes. **2000**, 175-188
- 30 Evaluation of adenosine deaminase (ADA) isoenzymes activity and tumor necrosis factor- α (TNF) concentration in chronic heart failure. **2014**, 13, 58-66 7
- 29 Myocardial recovery during mechanical circulatory support: cellular, molecular, genomic and organ levels. **2015**, 7, 110-20 1
- 28 Comparative evaluation of the left ventricular mass in patients with chronic kidney disease in periodontally healthy, chronic gingivitis, and chronic periodontitis patients. **2019**, 13, 13-18
- 27 Role of Cardiomyocyte Apoptosis in Heart Failure. **2022**, 253-267
- 26 Targeting Mediators of Inflammation in Heart Failure: A Short Synthesis of Experimental and Clinical Results. **2021**, 22, 2
- 25 Plasma-derived extracellular vesicles from myocardial infarction patients inhibits tumor necrosis factor-alpha induced cardiac cell death.. **2021**, 70, 103323 0
- 24 Methods of screening, monitoring and management of cardiac toxicity induced by chemotherapeutics?. **2022**, 1
- 23 Experimental models for investigating the pathogenesis of heart failure. **2022**, 103-122
- 22 Inflammation and Cardiovascular Diseases in the Elderly: The Role of Epicardial Adipose Tissue.. *Frontiers in Medicine*, **2022**, 9, 844266 4.9 2

21	Pro-Inflammatory Derangement of the Immuno-Interactome in Heart Failure.. <i>Frontiers in Immunology</i> , 2022 , 13, 817514	8.4	2
20	HDL Composition, Heart Failure, and Its Comorbidities.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 846990	5.4	1
19	Immunomodulatory Treatment Strategies Targeting B Cells for Heart Failure.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 854592	5.6	0
18	Biomarkers in the clinical management of patients with atrial fibrillation and heart failure.. <i>Journal of Geriatric Cardiology</i> , 2021 , 18, 908-951	1.7	2
17	Necroptosis and Viral Myocarditis: Tumor Necrosis Factor Is a Novel Biomarker for the Diagnosis of Viral Myocarditis. <i>Frontiers in Cell and Developmental Biology</i> , 2022 , 10,	5.7	0
16	Association between Serum GDF-15, Myostatin, and Sarcopenia in Cardiovascular Surgery Patients. <i>SSRN Electronic Journal</i> ,	1	
15	IL-10: A Key Molecule in the Mitigation of Heart Failure. 2022 , 257-271		
14	Pathophysiology of heart failure and an overview of therapies. 2022 , 149-221		
13	Correlation between Carotid Artery Mean Intima-Media Thickness and brain Natriuretic Peptide in Patients with Psoriasis. 247553032211180		
12	Tumor Necrosis Factor-Induced C-C Motif Chemokine Ligand 20 Expression through TNF Receptor 1-Dependent Activation of EGFR/p38 MAPK and JNK1/2/FoxO1 or the NF- κ B Pathway in Human Cardiac Fibroblasts. 2022 , 23, 9086		1
11	Association between serum GDF-15, myostatin, and sarcopenia in cardiovascular surgery patients. 2022 , 42, 101114		0
10	Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure.		0
9	An in vivo assessment of inflammatory and oxidative stress responses in Echis ocellatus-venom induced cardiotoxicity. 2022 , 5-6, 100017		0
8	Targeting the Autophagy-Lysosome Pathway in a Pathophysiologically Relevant Murine Model of Reversible Heart Failure. 2022 ,		0
7	Estimating the impact of drug addiction causes heart damage. 1-7		0
6	Advances in congestive heart failure biomarkers. 2022 ,		0
5	Levels of TNF- α and Soluble TNF Receptors in Normal-Weight, Overweight and Obese Patients with Dilated Non-Ischemic Cardiomyopathy: Does Anti-TNF Therapy Still Have Potential to Be Used in Heart Failure Depending on BMI?. 2022 , 10, 2959		0
4	PCSK9: A emerging participant in heart failure. 2023 , 158, 114106		1

- 3 Inflammation and Heart Failure: Searching for the Enemy Reaching the Entelechy. **2023**, 10, 19 o
- 2 Inflammation, dysregulated iron metabolism, and cardiovascular disease. 4, o
- 1 Treatment of Fabry Disease: Established and Emerging Therapies. **2023**, 16, 320 o